1 min read
CNS Pharmaceuticals Posts $0.24 Q3 Loss Per Share as Cash Reaches $17.2M
Cash and cash equivalents were $17.2 million at Sept. 30, up from $7.2 million at the end of 2025. The company believes its existing cash can fund planned operations beyond 12 months.

CNS Pharmaceuticals, Inc. (CNSP) had a third-quarter loss of $0.24 per share, compared with a loss of $5.76 per share in the same quarter a year earlier. The smaller per-share loss came alongside a higher cash balance at Sept. 30, 2026.
Cash and cash equivalents totaled $17.2 million at the end of the third quarter, up from $7.2 million on Dec. 31, 2025.
CNS Pharmaceuticals believes its existing cash resources are sufficient to fund planned operations beyond 12 months from the date its financial statements were issued.